Bayesian Methods in Pharmaceutical Research
Clasificación: | Libro Electrónico |
---|---|
Autor principal: | |
Otros Autores: | , |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Milton :
CRC Press LLC,
2020.
|
Colección: | Chapman and Hall/CRC Biostatistics Ser.
|
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover
- Half Title
- Series Page
- Title Page
- Copyright Page
- Dedication
- Contents
- Preface
- Editors
- Contributors
- List of abbreviations
- Part I: Introduction
- 1. Bayesian Background
- 1.1 Introduction
- 1.2 The frequentist approach to inference
- 1.3 Bayesian concepts
- 1.4 More than one parameter
- 1.5 Choosing the prior distribution
- 1.6 Determining the posterior distribution numerically
- 1.7 Hierarchical models and data augmentation
- 1.8 Model selection and model checking
- 1.9 Bayesian nonparametric methods
- 1.10 Bayesian software
- 1.11 Further reading
- 2. FDA Regulatory Acceptance of Bayesian Statistics
- 2.1 Introduction
- 2.2 Medical devices
- 2.3 Pharmaceutical products
- 2.4 Differences between devices and drugs
- 2.5 Some promising opportunities in pharmaceutical drugs
- 2.6 The future
- 2.7 Conclusion
- 3. Bayesian Tail Probabilities for Decision Making
- 3.1 Introduction
- 3.2 Posterior tail probabilities
- 3.3 Predictive tail probabilities
- 3.4 Discussion
- Part II: Clinical development
- 4. Clinical Development in the Light of Bayesian Statistics
- 4.1 Introduction
- 4.2 Introduction to drug development
- 4.3 Quantitative decision making in drug development
- 4.4 Bayesian thinking
- 4.5 Applications of Bayesian methods in drug development
- 4.6 Conclusion
- 5. Prior Elicitation
- 5.1 Introduction
- 5.2 Methods for prior elicitation
- 5.3 Examples
- 5.4 Impact and outlook
- 6. Use of Historical Data
- 6.1 Introduction
- 6.2 Identifying historical or co-data
- 6.3 An example: Guillain-Barré syndrome in children
- 6.4 Methods
- 6.5 Application: Non-inferiority trials
- 6.6 Discussion
- 6.7 Code
- 7. Dose Ranging Studies and Dose Determination
- 7.1 Introduction
- 7.2 Dose-response studies
- 7.3 Dose escalation trials in oncology
- 7.4 Conclusions
- 8. Bayesian Adaptive Designs in Drug Development
- 8.1 Introduction
- 8.2 Brief history of adaptive designs
- 8.3 What is an adaptive clinical trial?
- 8.4 Types of adaptation
- 8.5 Reasons we might consider adaptive designs
- 8.6 Example of an adaptive design
- 8.7 Adaptive enrichment designs
- 8.8 Some criticisms of adaptive designs
- 8.9 Summary
- 9. Bayesian Methods for Longitudinal Data with Missingness
- 9.1 Introduction
- 9.2 Common frequentist approaches
- 9.3 Bayesian approaches
- 9.4 Ignorable and nonignorable missingness
- 9.5 Posterior inference
- 9.6 Model selection
- 9.7 Model checking and assessment
- 9.8 Practical example: Growth hormone trial
- 9.9 Wrap-up and open problems
- 10. Survival Analysis and Censored Data
- 10.1 Introduction
- 10.2 Review of survival analysis
- 10.3 Software
- 10.4 Applications
- 10.5 Reporting
- 10.6 Other comments
- 11. Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine
- 11.1 Introduction
- 11.2 Motivating example